X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (39275) 39275
Book Review (4665) 4665
Publication (2938) 2938
Newsletter (803) 803
Book Chapter (533) 533
Conference Proceeding (220) 220
Dissertation (112) 112
Magazine Article (51) 51
Book / eBook (25) 25
Web Resource (13) 13
Reference (10) 10
Government Document (8) 8
Trade Publication Article (5) 5
Newspaper Article (4) 4
Paper (4) 4
Data Set (1) 1
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (32304) 32304
animals (19140) 19140
humans (16496) 16496
male (12626) 12626
rats (7069) 7069
phosphodiesterase inhibitors - pharmacology (6999) 6999
phosphodiesterase (5841) 5841
female (5825) 5825
biochemistry & molecular biology (5616) 5616
mice (4855) 4855
pharmacology & pharmacy (4748) 4748
cyclic amp - metabolism (3691) 3691
phosphodiesterase inhibitors - therapeutic use (3640) 3640
middle aged (3317) 3317
sildenafil citrate (3264) 3264
adult (2955) 2955
phosphodiesterases (2949) 2949
3',5'-cyclic-amp phosphodiesterases - metabolism (2812) 2812
kinetics (2744) 2744
neurosciences (2724) 2724
sildenafil (2678) 2678
in vitro techniques (2638) 2638
cell biology (2580) 2580
phosphoric diester hydrolases - metabolism (2580) 2580
dose-response relationship, drug (2563) 2563
phosphodiesterase inhibitors (2519) 2519
cells, cultured (2506) 2506
erectile dysfunction (2391) 2391
research (2365) 2365
erectile dysfunction - drug therapy (2299) 2299
aged (2216) 2216
enzymes (2205) 2205
expression (2120) 2120
signal transduction (2048) 2048
abridged index medicus (2043) 2043
camp (2007) 2007
cyclic gmp - metabolism (1996) 1996
analysis (1990) 1990
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (1975) 1975
phosphorylation (1957) 1957
urology & nephrology (1883) 1883
proteins (1798) 1798
time factors (1776) 1776
activation (1763) 1763
sphingomyelin phosphodiesterase - metabolism (1762) 1762
cells (1728) 1728
cattle (1719) 1719
rats, sprague-dawley (1713) 1713
molecular sequence data (1695) 1695
treatment outcome (1662) 1662
piperazines - therapeutic use (1631) 1631
purines (1616) 1616
physiological aspects (1545) 1545
physiology (1543) 1543
sulfones (1522) 1522
calcium - metabolism (1488) 1488
cardiac & cardiovascular systems (1487) 1487
disease models, animal (1436) 1436
inhibition (1423) 1423
cyclic amp (1418) 1418
nitric oxide (1418) 1418
cell line (1415) 1415
rats, wistar (1413) 1413
amino acid sequence (1409) 1409
enzyme inhibitors - pharmacology (1403) 1403
tadalafil (1401) 1401
article (1393) 1393
nitric-oxide (1370) 1370
1-methyl-3-isobutylxanthine - pharmacology (1332) 1332
apoptosis (1289) 1289
phosphodiesterase 5 inhibitors - therapeutic use (1266) 1266
impotence (1264) 1264
rolipram (1257) 1257
chemistry, medicinal (1239) 1239
enzyme activation (1204) 1204
phosphodiesterase inhibitors - administration & dosage (1191) 1191
mice, inbred c57bl (1163) 1163
inhibitors (1150) 1150
mutation (1149) 1149
adenylyl cyclases - metabolism (1143) 1143
cgmp (1136) 1136
piperazines - pharmacology (1126) 1126
gene expression (1121) 1121
identification (1090) 1090
brain (1080) 1080
inflammation (1071) 1071
3',5'-cyclic-gmp phosphodiesterases - metabolism (1069) 1069
rabbits (1040) 1040
calcium (1033) 1033
cyclic nucleotide phosphodiesterases, type 4 (1024) 1024
structure-activity relationship (1024) 1024
biophysics (1023) 1023
in-vitro (1020) 1020
health aspects (1010) 1010
phosphodiesterase inhibitors - adverse effects (1002) 1002
hydrolysis (989) 989
multidisciplinary sciences (986) 986
cyclic-nucleotide phosphodiesterases (968) 968
respiratory system (950) 950
base sequence (948) 948
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (12) 12
Online Resources - Online (9) 9
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Gerstein Science - Theses (1) 1
University Archives - Archives (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (38444) 38444
German (476) 476
Russian (474) 474
Japanese (314) 314
French (282) 282
Chinese (217) 217
Spanish (177) 177
Italian (54) 54
Portuguese (47) 47
Polish (38) 38
Korean (31) 31
Swedish (17) 17
Hungarian (15) 15
Turkish (15) 15
Czech (14) 14
Dutch (12) 12
Danish (10) 10
Hebrew (9) 9
Norwegian (8) 8
Finnish (7) 7
Croatian (6) 6
Ukrainian (6) 6
Bulgarian (4) 4
Slovak (4) 4
Serbian (3) 3
Romanian (2) 2
Slovenian (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1992, ISBN 0881678201, Volume 25., xvii, 429 p. : ill. ; 24 cm.
Book
Nature Biotechnology, ISSN 1087-0156, 01/2010, Volume 28, Issue 1, pp. 63 - 70
Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions. Here we present seven... 
CAMP-SPECIFIC PHOSPHODIESTERASE | PHOSPHORYLATION | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | PROTEIN-KINASE | GENE COMPOSER | SUNCUS-MURINUS | AMP-SPECIFIC PHOSPHODIESTERASE | INHIBITORS | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | ROLIPRAM BINDING | ANTIDEPRESSANT DRUGS | Phosphodiesterase Inhibitors - therapeutic use | Phosphodiesterase Inhibitors - adverse effects | Humans | Molecular Sequence Data | Crystallography, X-Ray | Structure-Activity Relationship | Benzhydryl Compounds - chemistry | Benzhydryl Compounds - adverse effects | Phenylurea Compounds - adverse effects | Phenylurea Compounds - chemistry | Drug Design | Phosphodiesterase 4 Inhibitors | Behavior, Animal - drug effects | Biological Assay | Phosphodiesterase Inhibitors - chemistry | Benzhydryl Compounds - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Disease Models, Animal | Allosteric Regulation - drug effects | Protein Structure, Tertiary | Amino Acid Sequence | Cell Line | Catalytic Domain | Models, Molecular | Phenylurea Compounds - therapeutic use | Phosphodiesterase Inhibitors - pharmacology | Vomiting - drug therapy | Cognition - drug effects | Animals | Benzhydryl Compounds - pharmacology | Mice | Phenylurea Compounds - pharmacology | Kinetics | Care and treatment | Schizophrenia | Physiological aspects | Genetic aspects | Cellular signal transduction | Cyclic adenylic acid | Research | Phosphodiesterases | Enzymes | Biotechnology | Cellular biology | Molecular biology | Cognitive ability | Crystal structure | Index Medicus
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 05/1999, Volume 127, Issue 1, pp. 65 - 74
The effects of several phosphodiesterase (PDE) inhibitors on the L‐type Ca current ( I Ca ) and intracellular cyclic AMP concentration ([cAMP] i ) were... 
cilostamide (PDE3 inhibitor) | intracellular cyclic AMP | phosphodiesterase subtypes | current | Ro20‐1724 (PDE4 inhibitor) | L‐type Ca | EHNA (PDE2 inhibitor) | phosphodiesterase inhibitors | MIMX (PDE1 inhibitor) | β‐adrenoceptor agonist | Rat heart | Cilostamide (PDE3 inhibitor) | β-adrenoceptor agonist | Intracellular cyclic AMP | Phosphodiesterase subtypes | L-type Ca | Phosphodiesterase inhibitors | Ro20-1724 (PDE4 inhibitor) | MYOCARDIUM | CELLS | ISOFORMS | BIOCHEMISTRY & MOLECULAR BIOLOGY | L-type Ca2+ current | beta-adrenoceptor agonist | CARDIAC MYOCYTES | CALCIUM CURRENT | rat heart | DEPENDENT PROTEIN-KINASE | FATTY-ACIDS | AMP PHOSPHODIESTERASES | GMP | PHARMACOLOGY & PHARMACY | HUMAN ATRIAL MYOCYTES | Cyclic Nucleotide Phosphodiesterases, Type 1 | Heart Ventricles - cytology | Calcium Channels - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 | Rats, Wistar | Cyclic Nucleotide Phosphodiesterases, Type 3 | Calcium Channels, L-Type | Male | 3',5'-Cyclic-AMP Phosphodiesterases - physiology | Cyclic AMP - physiology | 3',5'-Cyclic-AMP Phosphodiesterases - biosynthesis | Calcium - physiology | Heart Ventricles - enzymology | Myocardium - metabolism | 3',5'-Cyclic-GMP Phosphodiesterases - biosynthesis | 3',5'-Cyclic-GMP Phosphodiesterases - physiology | Adrenergic beta-Agonists - pharmacology | Phosphodiesterase Inhibitors - pharmacology | Rats | Reverse Transcriptase Polymerase Chain Reaction | Myocardium - cytology | Phosphoric Diester Hydrolases | Myocardium - enzymology | Patch-Clamp Techniques | Animals | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | 3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors | Isoproterenol - pharmacology | Heart Ventricles - metabolism | In Vitro Techniques | Index Medicus | Papers
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2008, Volume 105, Issue 49, pp. 19532 - 19537
Cyclic nucleotide phosphodiesterase (PDE) isoforms can influence disease pathogenesis and be novel therapeutic targets. Because lower cAMP levels may... 
Protein isoforms | T lymphocytes | Chronic lymphocytic leukemia | Messenger RNA | Cyclic nucleotides | B lymphocytes | Medical treatment | Apoptosis | Vehicles | B cell leukemia | B cell | Survivin | cAMP | survivin | CELLS | CAMP-SPECIFIC PHOSPHODIESTERASE | AMP | INHIBITOR-INDUCED APOPTOSIS | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | apoptosis | HUMAN B-LYMPHOCYTES | THEOPHYLLINE | PATHWAY | THERAPEUTIC TARGET | GENE-EXPRESSION | Cyclic Nucleotide Phosphodiesterases, Type 3 - genetics | Cyclic Nucleotide Phosphodiesterases, Type 4 | Humans | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | RNA, Messenger - metabolism | Enzyme Activation - immunology | Cell Division - immunology | Cyclic Nucleotide Phosphodiesterases, Type 7 - genetics | Leukemia, Lymphocytic, Chronic, B-Cell - physiopathology | Membrane Potential, Mitochondrial | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Cyclic AMP-Dependent Protein Kinases - metabolism | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | B-Lymphocytes - cytology | B-Lymphocytes - enzymology | Phosphodiesterase 3 Inhibitors | Cells, Cultured | Cyclic Nucleotide Phosphodiesterases, Type 7 - metabolism | Phosphodiesterase Inhibitors - pharmacology | 3',5'-Cyclic-AMP Phosphodiesterases - genetics | Gene Expression Regulation, Leukemic | Gene Expression Regulation, Enzymologic | Apoptosis - immunology | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Cyclic Nucleotide Phosphodiesterases, Type 7 - antagonists & inhibitors | Physiological aspects | Genetic aspects | Cyclic adenylic acid | Research | Drug therapy | Phosphodiesterases | Enzymes | Protein folding | Leukemia | Gene expression | Ribonucleic acid--RNA | Cells | Index Medicus | Biological Sciences
Journal Article
Cellular Signalling, ISSN 0898-6568, 09/2014, Volume 26, Issue 9, pp. 2016 - 2029
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in... 
Phosphodiesterase inhibitor | Apremilast | Spondyloarthropathies | Psoriasis | Preclinical drug evaluation | Psoriatic arthritis | PROTEIN-KINASE-A | CONTROLLED-TRIAL | CAMP-SPECIFIC PHOSPHODIESTERASE | NECROSIS-FACTOR-ALPHA | KAPPA-B | PSORIATIC-ARTHRITIS | CELL BIOLOGY | ORAL PHOSPHODIESTERASE-4 INHIBITOR | CYCLIC-AMP | THALIDOMIDE ANALOGS | B-MEDIATED TRANSCRIPTION | Thalidomide - metabolism | Humans | Male | Thalidomide - pharmacology | Lung Diseases - drug therapy | Thalidomide - analogs & derivatives | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Female | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Vomiting - prevention & control | B-Lymphocytes - metabolism | Disease Models, Animal | Cell Line | Cytokines - metabolism | Immunity, Innate - drug effects | Jurkat Cells | Phosphodiesterase 4 Inhibitors - therapeutic use | Mice, Transgenic | Phosphodiesterase 4 Inhibitors - metabolism | Ferrets | Phosphodiesterase 4 Inhibitors - pharmacology | B-Lymphocytes - drug effects | Adaptive Immunity - drug effects | Animals | B-Lymphocytes - immunology | Protein Binding | T-Lymphocytes - immunology | Mice | Thalidomide - therapeutic use | Dendritic cells | Analysis | Development and progression | Genetic engineering | B cells | Biological response modifiers | T cells | Index Medicus
Journal Article
Nature, ISSN 0028-0836, 03/2015, Volume 519, Issue 7544, pp. 472 - 476
Journal Article
Molecular and Cellular Endocrinology, ISSN 0303-7207, 03/2015, Volume 403, Issue C, pp. 10 - 20
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 01/2013, Volume 23, Issue 1, pp. 375 - 381
(−)-6-(7-Methoxy-2-(trifluoromethyl)pyrazolo[1,5- ]pyridin-4-yl)-5-methyl-4,5-dihydropyridazin-3(2 )-one (KCA-1490) exhibits moderate dual PDE3/4-inhibitory... 
Phosphodiesterase (PDE) | Inhaled administration | Dual PDE3/4 inhibitor | Asthma | COPD | MORTALITY | CHRONIC HEART-FAILURE | BRONCHODILATORY ACTIVITY | DESIGN | CHEMISTRY, MEDICINAL | CHEMISTRY, ORGANIC | 4,5-DIHYDRO-6-<4-(1H-IMIDAZOL-1-YL)PHENYL>-3(2H)-PYRIDAZINONES | OBSTRUCTIVE PULMONARY-DISEASE | POSITIVE INOTROPIC AGENTS | CORTICOSTEROIDS | CARDIOTONIC AGENTS | ROFLUMILAST | Cyclic Nucleotide Phosphodiesterases, Type 3 - chemistry | Phosphodiesterase 3 Inhibitors - chemistry | Phosphodiesterase 3 Inhibitors - pharmacology | Pyridines - chemistry | Structure-Activity Relationship | Phosphodiesterase 4 Inhibitors - chemical synthesis | Bronchodilator Agents - chemistry | Drug Design | Bronchoalveolar Lavage Fluid - cytology | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Phosphodiesterase 4 Inhibitors - chemistry | Anti-Inflammatory Agents - pharmacology | Administration, Inhalation | Rats | Bronchodilator Agents - pharmacology | Bronchodilator Agents - chemical synthesis | Phosphodiesterase 4 Inhibitors - pharmacology | Pyridazines - chemistry | Phosphodiesterase 3 Inhibitors - chemical synthesis | Animals | Anti-Inflammatory Agents - chemistry | Protein Binding | Leukocytes - drug effects | Anti-Inflammatory Agents - chemical synthesis | Anti-inflammatory drugs | Respiratory agents | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 07/2007, Volume 116, Issue 3, pp. 238 - 248
Background - Sildenafil was recently approved for the treatment of pulmonary arterial hypertension. The beneficial effects of phosphodiesterase type 5 (PDE5)... 
Inhibitors | Inotropic agents | Contractility | Hypertension, pulmonary | Hypertrophy | inhibitors | CARDIAC & CARDIOVASCULAR SYSTEMS | ORAL SILDENAFIL | hypertrophy | PULMONARY ARTERIAL-HYPERTENSION | contractility | HEART-FAILURE | SILDENAFIL CITRATE | pulmonary | DEPENDENT PROTEIN-KINASE | NATRIURETIC PEPTIDE | INHALED NITRIC-OXIDE | CYCLIC-GMP PHOSPHODIESTERASE | inotropic agents | IN-VITRO | PERIPHERAL VASCULAR DISEASE | CARDIAC CONTRACTILITY | HEMATOLOGY | hypertension | Gene Expression Regulation, Enzymologic - drug effects | Phosphodiesterase Inhibitors - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 5 | 3',5'-Cyclic-GMP Phosphodiesterases - genetics | Humans | Middle Aged | Myocardial Contraction - physiology | Child, Preschool | Myocardial Contraction - drug effects | Phosphodiesterase Inhibitors - pharmacology | Rats | Infant | Male | Gene Expression Regulation, Enzymologic - physiology | Hypertrophy, Right Ventricular - enzymology | Rats, Sprague-Dawley | Hypertrophy, Right Ventricular - drug therapy | Animals | 3',5'-Cyclic-GMP Phosphodiesterases - antagonists & inhibitors | Adult | Female | 3',5'-Cyclic-GMP Phosphodiesterases - biosynthesis | Infant, Newborn | Physiological aspects | Care and treatment | Phosphodiesterases | Pulmonary hypertension | Heart ventricle, Right | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Molecular and Cellular Cardiology, ISSN 0022-2828, 2015, Volume 88, pp. 29 - 38
Abstract In cardiac myocytes, the second messenger cAMP is synthesized within the β-adrenergic signaling pathway upon sympathetic activation. It activates... 
Cardiovascular | β-adrenergic pathway | Cyclic nucleotides | Computational model | Signaling networks | Cardiac myocytes | Phosphodiesterase | CARDIAC & CARDIOVASCULAR SYSTEMS | COMPUTATIONAL MODELS | HEART-FAILURE | beta-adrenergic pathway | CAMP EARLY REPRESSOR | CGMP PHOSPHODIESTERASES | PROTEIN-KINASES | FEEDBACK LOOP | CELL BIOLOGY | CARDIOMYOCYTE APOPTOSIS | NITRIC-OXIDE | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | RAT VENTRICULAR MYOCYTES | Cyclic Nucleotide Phosphodiesterases, Type 3 - genetics | Phosphorylation | Humans | Myocardial Contraction - physiology | Cyclic Nucleotide Phosphodiesterases, Type 2 - genetics | Cyclic AMP-Dependent Protein Kinases - genetics | Myocardium - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Binding Sites | Cyclic AMP - metabolism | Binding, Competitive | Cyclic AMP-Dependent Protein Kinases - metabolism | Myocytes, Cardiac - cytology | Signal Transduction | Models, Cardiovascular | Cyclic Nucleotide Phosphodiesterases, Type 2 - metabolism | Gene Expression Regulation | Cyclic Nucleotide Phosphodiesterases, Type 1 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Feedback, Physiological | Animals | Cyclic GMP - metabolism | Myocytes, Cardiac - metabolism | Protein Binding | Mice | Cyclic Nucleotide Phosphodiesterases, Type 1 - genetics | Index Medicus
Journal Article